文献速递脑血管病外科神经重症

动脉瘤性蛛网膜下腔出血中的继发性出血并发症:当影响来临时

Secondary hemorrhagic complications in aneurysmal subarachnoid hemorrhage: when the impact hits hard.
PubMed 文献 · J Neurosurg · 2019-01-25

该研究纳入2003年1月至2016年6月间连续收治的939例破裂动脉瘤患者,分析继发性出血并发症(SHC)的发生率、危险因素及对预后的影响。62例(6.6%)发生SHC,脑室造瘘相关出血由抗血小板治疗独立预测但未影响功能预后;围介入期使用溶栓药物是主要SHC的唯一独立预测因素,而主要SHC与6个月随访不良预后独立相关。

要点

  • 939例动脉瘤性蛛网膜下腔出血患者中62例(6.6%)发生继发性出血并发症。
  • 脑室造瘘相关出血由动脉瘤治疗后单药或双联抗血小板治疗独立预测,但未影响功能预后。
  • 围介入期使用溶栓药物是主要继发性出血并发症的唯一独立预测因素,主要出血与6个月不良预后独立相关。

核心结论

  • 继发性出血并发症是蛛网膜下腔出血的罕见后遗症,抗血小板治疗(而非出血前抗凝)增加脑室造瘘相关出血风险但不影响病程和预后,围介入期溶栓药物使用带来主要出血和不良预后的相关风险。

研究设计与样本

  • 回顾性队列研究,纳入2003年1月至2016年6月间连续收治的破裂动脉瘤患者939例,复习病历和影像学资料,将继发性出血并发症分为脑室造瘘相关与非脑室造瘘相关,以及主要与次要出血形式。

主要发现

  • 939例患者中62例(6.6%)发生继发性出血并发症;脑室造瘘相关出血16例,由动脉瘤治疗后单药抗血小板治疗(p=0.028,aOR=10.28)或双联抗血小板治疗(p=0.026,aOR=14.25)独立预测,但未影响功能预后。
  • 主要继发性出血并发症38例(61.3%),在血管内治疗患者中,围介入期使用溶栓药物进行早期有效抗凝是唯一独立预测因素(p=0.010,aOR=4.27)。
  • 主要继发性出血并发症与6个月随访时不良预后(改良Rankin量表评分>3)独立相关;蛛网膜下腔出血前使用血液稀释药物治疗与继发性出血并发症风险无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Clinical data on secondary hemorrhagic complications (SHCs) in patients with aneurysmal subarachnoid hemorrhage (SAH) are sparse and mostly limited to ventriculostomy-associated SHCs. This study aimed to elucidate the incidence, risk factors, and impact on outcome of SHCs in a large cohort of SAH patients. METHODS: All consecutive patients with ruptured aneurysms treated between January 2003 and June 2016 were eligible for this study. Patients' charts were reviewed for clinical data, and imaging studies were reviewed for radiographic data. SHCs were divided into those associated with ventriculostomy and those not associated with ventriculostomy, as well as into major and minor bleeding forms, depending on clinical impact. RESULTS: Sixty-two (6.6%) of the 939 patients included in the final analysis developed SHCs. Ventriculostomy-associated bleedings (n = 16) were independently predicted by mono- or dual-antiplatelet therapy after aneurysm treatment (p = 0.028, adjusted odds ratio [aOR] = 10.28; and p = 0.026, aOR = 14.25, respectively) but showed no impact on functional outcome after SAH. Periinterventional use of thrombolytic agents for early effective anticoagulation was the only independent predictor (p = 0.010, aOR = 4.27) of major SHCs (n = 38, 61.3%) in endovascularly treated patients. In turn, a major SHC was independently associated with poor outcome at the 6-month follow-up (modified Rankin Scale score > 3). Blood thinning drug therapy prior to SAH was not associated with SHC risk. CONCLUSIONS: SHCs present a rare sequela of SAH. Antiplatelet therapy during (but not before) SAH increases the risk of ventriculostomy-associated bleedings, but without further impact on the course and outcome of SAH. The use of thrombolytic agents for early effective anticoagulation carries relevant risk for major SHCs and poor outcome.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Darkwah Oppong M, Buffen K, Pierscianek D, et al. Secondary hemorrhagic complications in aneurysmal subarachnoid hemorrhage: when the impact hits hard. J Neurosurg. 2019. PMID: 30684947. doi:10.3171/2018.9.JNS182105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。